Kang Pharmaceuticals-B (02410.HK) announced that on September 13, 2024, the company has submitted an application to the China Securities Regulatory Commission for the conversion of 0.174 billion non-listed shares into H shares and the listing of these shares on the Hong Kong Stock Exchange. After obtaining record-filing and/or approval from all relevant regulatory institutions (including but not limited to the China Securities Regulatory Commission and the Hong Kong Stock Exchange), and complying with all applicable laws, regulations, and rules, these non-listed shares will be converted into H shares and be eligible for trading on the main board of the Hong Kong Stock Exchange.
同源康医药-B(02410.HK)申请H股全流通
Tongyuan Kang Pharmaceutical-B (02410.HK) applies for full circulation of H shares.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.